European journal of preventive cardiology最新文献

{"title":"What do recent observations reveal about the \"blind date\" with Lp(a)-reducing drugs?","authors":"Florian Kronenberg","doi":"10.1093/eurjpc/zwaf324","DOIUrl":"https://doi.org/10.1093/eurjpc/zwaf324","url":null,"abstract":"","PeriodicalId":12051,"journal":{"name":"European journal of preventive cardiology","volume":" ","pages":""},"PeriodicalIF":8.4,"publicationDate":"2025-06-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144208096","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Predictive modelling of medication adherence in post-myocardial infarction patients: a Bayesian approach using beta-regression.","authors":"Elias Edward Tannous, Shlomo Selitzky, Shlomo Vinker, David Stepensky, Eyal Schwarzberg","doi":"10.1093/eurjpc/zwae327","DOIUrl":"10.1093/eurjpc/zwae327","url":null,"abstract":"<p><strong>Aims: </strong>Predicting medication adherence in post-myocardial infarction (MI) patients has the potential to improve patient outcomes. Most adherence prediction models dichotomize adherence metrics and status. This study aims to develop medication adherence prediction models that avoid dichotomizing adherence metrics and to test whether a simplified model including only 90-days adherence data would perform similarly to a full multi-variable model.</p><p><strong>Methods and results: </strong>Post-MI adult patients were followed for 1-year post the event. Data from pharmacy records were used to calculate proportion of days covered (PDC). We used Bayesian beta-regression to model PDC as a proportion, avoiding dichotomisation. For each medication group, statins, P2Y12 inhibitors and aspirin, two prediction models were developed, a full and a simplified model. 3692 patients were included for model development. The median (inter-quartile range) PDC at 1-year for statins, P2Y12 inhibitors and aspirin was 0.8 (0.33, 1.00), 0.79 (0.23, 0.99), and 0.79 (0.23, 0.99), respectively. All models showed good fit to the data by visual predictive checks. Bayesian R2 for statins, P2Y12 inhibitors and aspirin models were 61.4%, 71.2%, and 55.2%, respectively. The simplified models showed similar performance compared with full complex models as evaluated by cross validation.</p><p><strong>Conclusion: </strong>We developed Bayesian multi-level models for statins, P2Y12 inhibitors and aspirin in post-MI patients that handled 1-year PDC as a proportion using the beta-distribution. In addition, simplified models, with 90-days adherence as single predictor, had similar performance compared with full complex models.</p><p><strong>Lay summary: </strong>Predicting adherence to medications in patients after myocardial infarction may help focusing resources on patients with the highest need for medical attention. Medication adherence is usually calculated from prescription filling data. Most previously published prediction models categorized patients as 'adherent' or 'non-adherent' and then tried to predict to which category a certain patient would belong. We suggest here a method to avoid the need for such categorisation. This method can successfully predict the extent of prescription filling. Moreover, we found that simple prediction models, needing only information on the first 3 months prescription filling behaviour, was as good as complex models that required many predictors.</p>","PeriodicalId":12051,"journal":{"name":"European journal of preventive cardiology","volume":" ","pages":"649-658"},"PeriodicalIF":8.4,"publicationDate":"2025-06-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142375341","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Beta-Blockers after myocardial infarction: returning from injured reserve.","authors":"Gilles Montalescot, Louis Giovachini, Johanne Silvain","doi":"10.1093/eurjpc/zwaf080","DOIUrl":"10.1093/eurjpc/zwaf080","url":null,"abstract":"","PeriodicalId":12051,"journal":{"name":"European journal of preventive cardiology","volume":" ","pages":"647-648"},"PeriodicalIF":8.4,"publicationDate":"2025-06-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143448351","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Are familial risks of myocardial infarction with non-obstructive coronary arteries shared with obstructive coronary artery disease?","authors":"Cathevine Yang, Jacqueline Saw","doi":"10.1093/eurjpc/zwaf133","DOIUrl":"10.1093/eurjpc/zwaf133","url":null,"abstract":"","PeriodicalId":12051,"journal":{"name":"European journal of preventive cardiology","volume":" ","pages":"680-681"},"PeriodicalIF":8.4,"publicationDate":"2025-06-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143984458","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association of longitudinal triglyceride levels with cardiovascular events in multivessel coronary artery disease.","authors":"Arthur Cicupira Rodrigues de Assis, Paulo Cury Rezende, Whady Hueb, Ary Serpa Neto, Thiago Luis Scudeler, Rosa Maria Rahmi Garcia, Vitor Coutinho Andrade, Marcela Francisca da Silva, Matheus de Oliveira Laterza Ribeiro, Mauricio Rigodanzo Mocha, Maria Stanislavovna Tairova, Luciano da Silva Selistre, Paulo Rogerio Soares, Jose Antonio Franchini Ramires, Roberto Kalil Filho","doi":"10.1093/eurjpc/zwaf192","DOIUrl":"https://doi.org/10.1093/eurjpc/zwaf192","url":null,"abstract":"<p><strong>Aims: </strong>The impact of longitudinal fluctuations in triglyceride levels on clinical outcomes in stable coronary artery disease (CAD) is yet to be clarified. This study aims to assess the association between increased upward variability in longitudinal fasting triglyceride levels and the incidence of cardiovascular events during long-term follow-up in patients with multivessel CAD.</p><p><strong>Methods and results: </strong>This cohort study included 1020 patients with multivessel CAD in the Medicine, Angioplasty, or Surgery Study Registry of the Heart Institute, University of São Paulo, from June 1995 to March 2010. Of 1020 patients with multivessel CAD, 886 had complete clinical and fasting triglyceride levels information during a mean follow-up period of 10.0 years, with a mean of 9.2 triglyceride measurements for each patient. The composite endpoint of death, myocardial infarction, ischaemic stroke, or unplanned myocardial revascularization occurred in 357 patients. A 100 mg/dL increase in the longitudinal triglyceride levels was significantly associated with a 19% higher risk of the combined endpoint [hazard ratio (HR), 1.19 (95% confidence interval (CI), 1.05-1.34); P = 0.008] in the unadjusted analysis. After multivariable adjustment for key baseline factors, this elevation in longitudinal triglyceride levels was associated with a 26% greater risk of the composite endpoint [HR, 1.26 (95% CI, 1.10-1.41); P < 0.001]. Triglyceride variability was also assessed according to baseline triglyceride levels (<150 and ≥ 150 mg/dL). These analyses showed that 100 mg/dL increase in the < 150 mg/dL group was associated with higher cardiovascular risk-HR 1.49 (95% CI, 1.00-1.93, P = 0.029)-compared with the ≥ 150 mg/dL group, HR 1.15 (95% CI, 0.99-1.39, P = 0.214)-both after multivariable analyses.</p><p><strong>Conclusion: </strong>Increased upward variation of longitudinal fasting triglyceride levels was independently associated with higher rates of cardiovascular outcomes in patients with multivessel CAD. This association was especially observed in individuals with previously controlled triglyceride levels but not in those with elevated baseline levels.</p><p><strong>Lay summary: </strong>Triglycerides are intricately associated with metabolic disorders that contribute to atherosclerotic events; however, the relationship between individual triglyceride trajectories and adverse cardiovascular outcomes in individuals with stable coronary artery disease (CAD) remains unclear. Using a cohort of 1020 patients with chronic CAD under long-term follow-up, we observed that greater triglyceride variability was associated with an increased cardiovascular risk, and this risk remained significant in individuals who previously had controlled triglyceride levels compared with those with persistently altered levels since baseline.</p>","PeriodicalId":12051,"journal":{"name":"European journal of preventive cardiology","volume":" ","pages":""},"PeriodicalIF":8.4,"publicationDate":"2025-06-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144198625","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sweetened Beverages and Degenerative Valve Disease: Time to Sip with Caution?","authors":"Erwan Donal, Prayuth Rasmeehirun","doi":"10.1093/eurjpc/zwaf317","DOIUrl":"https://doi.org/10.1093/eurjpc/zwaf317","url":null,"abstract":"","PeriodicalId":12051,"journal":{"name":"European journal of preventive cardiology","volume":" ","pages":""},"PeriodicalIF":8.4,"publicationDate":"2025-05-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144191681","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Physical activity and health benefits: shorter means safer.","authors":"Viktor Čulić","doi":"10.1093/eurjpc/zwaf316","DOIUrl":"https://doi.org/10.1093/eurjpc/zwaf316","url":null,"abstract":"","PeriodicalId":12051,"journal":{"name":"European journal of preventive cardiology","volume":" ","pages":""},"PeriodicalIF":8.4,"publicationDate":"2025-05-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144191680","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"External validation of the 2023 American Heart Association Predicting Risk of cardiovascular disease EVENTs equations for atherosclerotic cardiovascular disease in primary cardiovascular prevention setting and comparison with 2021 Systematic COronary Risk Evaluation and 2013 Pooled Cohort Equations.","authors":"de La Harpe Roxane, Marques-Vidal Pedro, Vaucher Julien","doi":"10.1093/eurjpc/zwaf213","DOIUrl":"https://doi.org/10.1093/eurjpc/zwaf213","url":null,"abstract":"<p><strong>Aims: </strong>External validation of the new 10-year PREVENT risk score for atherosclerotic cardiovascular disease (ASCVD) is important to assess its potential clinical applicability in Switzerland and to highlight its influence in preventive treatment eligibility.</p><p><strong>Methods and results: </strong>This study, which was not used in the development process of PREVENT, included 5064 individuals from a prospective Swiss cohort, aged 40 or older, without pre-existing ASCVD, and with complete data for risk score calculation. Main outcomes were adjudicated ASCVD events, including fatal and non-fatal myocardial infarction and strokes. The performances of the PREVENT score were assessed overall, and stratified by gender and age groups (<70 vs. ≥70 years), and compared with SCORE2 and the Pooled Cohort Equation (PCE) scores. Among 4356 participants followed from 2009 to 2012 over a median of 9 years, 224 experienced a first incident of ASCVD. The PREVENT cardiovascular risk prediction model demonstrated adequate discrimination performance, correctly identifying 76% of concordant pairs [C-Index, 95% Confidence Interval (CI) 0.73 to 0.79]. The model's calibration performances suggest systematic underestimation (Observed/Expected ratio 1.45, 95% CI 1.44-1.46), especially in women and those under 70 years old, yet it maintained positive clinical utility across all subgroups, particularly at the 7.5% threshold, which is the lower limit of the intermediate-risk category in clinical practice. However, PREVENT did not improve predictive performance when compared with SCORE2 and PCE.</p><p><strong>Conclusion: </strong>Our study confirmed the PREVENT model demonstrated adequate discrimination and calibration capabilities, along with significant clinical utility, particularly at intermediate-risk thresholds. However, it did not outperform the established models, SCORE2 or PCE. Additionally, PREVENT may systematically underestimate risk, which could raise concerns about the underprescription of preventive treatments.</p>","PeriodicalId":12051,"journal":{"name":"European journal of preventive cardiology","volume":" ","pages":""},"PeriodicalIF":8.4,"publicationDate":"2025-05-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144186855","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Variability in Lipids, Variability in Risk? A Call for Rigour in Cardiovascular Prognostics.","authors":"Taha Bhatti, Zain Nadeem, Dean Whaley","doi":"10.1093/eurjpc/zwaf320","DOIUrl":"https://doi.org/10.1093/eurjpc/zwaf320","url":null,"abstract":"","PeriodicalId":12051,"journal":{"name":"European journal of preventive cardiology","volume":" ","pages":""},"PeriodicalIF":8.4,"publicationDate":"2025-05-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144173297","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"External validation of cardiovascular risk scores in patients with Type 2 diabetes using the Spanish population-based CARDIANA cohort.","authors":"Mónica Enguita-Germán, Asier Ballesteros-Domínguez, Ibai Tamayo, Julián Librero, Ignacio Oscoz-Villanueva, Lluis Forga, Maria José Goñi-Iriarte, Javier Lafita, Oscar Lecea, Naiara Parraza, Berta Ibáñez-Beroiz","doi":"10.1093/eurjpc/zwaf304","DOIUrl":"https://doi.org/10.1093/eurjpc/zwaf304","url":null,"abstract":"<p><strong>Aims: </strong>There is an overabundance of cardiovascular disease (CVD) risk-prediction models applicable to patients with Type 2 diabetes (T2D), but most of them still require external validation. Our aim was to assess the performance of 18 CVD risk scores in a Spanish cohort of patients with T2D.</p><p><strong>Methods and results: </strong>The CARdiovascular Risk in patients with DIAbetes in Navarra (CARDIANA) cohort, which includes 20 793 individuals with T2D and no history of CVD, was used to externally validate 13 models developed in patients with T2D [Action in Diabetes and Vascular Disease (ADVANCE), Atherosclerosis Risk in Communities, Basque Country Prospective Complications and Mortality Study risk engine, Cardiovascular Healthy Study, Diabetes Cohort Study, DIAL2, DIAL2-extended, Fremantle, Kaasenbrood, Swedish National Diabetes Register (NDR), PREDICT1-diabetes, SCORE2-diabetes, and Wan] and 5 models developed in the general population (ASCVD, PREVENT-basic, PREVENT-full, QRISK2, and SCORE2). Harrell's C-statistic and calibration plots were used as measures of discrimination and calibration, respectively. There were 991 incident CVD events within 5 years of follow-up, resulting in a cumulative incidence of 5.0% (95% confidence interval 4.7-5.3). Discrimination ability was moderate for all the models, with SCORE2-diabetes, NDR, PREDICT1-diabetes, PREVENT-full, Wan, ADVANCE, and both DIAL2 models showing the highest C-index values. All models showed good calibration, although most of them required recalibration, with the exception of ADVANCE-, DIAL2-, and SCORE2-related models.</p><p><strong>Conclusion: </strong>In our context, models derived for or adapted to diabetes patients, as well as models derived in the general population but incorporating diabetes-related metabolic measures (such as Hb1Ac) as predictors, demonstrated better performance than the others. DIAL2, DIAL2-extended, SCORE2-diabetes, and ADVANCE showed optimal calibration even without recalibration, which implies greater applicability, especially for SCORE2-diabetes and ADVANCE because of their simplicity.</p>","PeriodicalId":12051,"journal":{"name":"European journal of preventive cardiology","volume":" ","pages":""},"PeriodicalIF":8.4,"publicationDate":"2025-05-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144173276","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}